Search consultations



Proposal to change funded branded of atomoxetine (ADHD medicine)

NZNO seeks your feedback on a PHARMAC proposal to remove all funding restrictions from all presentations of atomoxetine, and change the funded brand of atomoxetine from Strattera to a brand supplied by Generic Partners (NZ) Limited. The Generic Partners brand of atomoxetine would be listed from 1 July 2019, and the community and hospital funding restrictions on atomoxetine would be removed at the same time. There would then be a transition period, detailed below, after which Strattera would be delisted. The Generic Partners brand of atomoxetine would be awarded sole supply from 1 December 2019 until 30 June 2022, meaning that it would be the only funded brand of atomoxetine during this time.

Please send feedback to by 16 JANUARY 2019


Notify me when this page changes

Enter your email address below to receive alerts when this page is updated.

Sign up below to receive an email when we update this page

Enter the code shown above in the box below.